Oxfam report says top drug companies focusing on patents, not the poor

Get RSS feed of these results

All components of this story

Article
12 December 2007

Oxfam report "Investing for Life": Company responses

Author: Compiled by the Business & Human Rights Resource Centre

The Business & Human Rights Resource Centre invited all 12 [pharmaceutical] companies to respond to the report. The results to date are below (any future responses received will be added to this page)...On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses...
- Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis responded
- Roche, Eli Lilly declined to respond
- Bristol-Myers Squibb, Wyeth did not respond

Read the full post here

Article
+ Español - Hide

Author: Oxfam

La industria farmacéutica niega el acceso a medicamentos básicos a millones de personas y socava su propio futuro, debido a la negativa de las compañías a cambiar sus estrategias de negocio en los mercados de los países en vías de desarrollo, según alerta Oxfam Internacional...El informe "Invertir en la vida. Cómo lograr el acceso a medicamentos esenciales a través de prácticas empresariales responsables" pone la lupa en las 12 principales compañías farmacéuticas mundiales. [se refiere a Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis y Wyeth]

🚫Read the full post here

Article
26 November 2007

Oxfam says top drug companies focusing on patents, not poor

Author: Bhuma Shrivastava, Livemint.com [India]

A report by…[Oxfam International] has criticized the world’s top drug makers for their unwillingness to practice tiered pricing and discover drugs targeting so-called poor man’s diseases…and insistence on intellectual property rights at the cost of making drugs accessible to the people who need them most…The report categorizes all 12 drug makers as “defensive” in terms of their attitude towards patents…Ranga Iyer, the…head of the multinational drug makers lobby…[in India]… said that companies alone could not solve the problem and that all stakeholders, including the government, needed to play a role…[refers to Novartis, Wyeth]

Read the full post here

Article
+ Français - Hide

Author: Organisation de la Presse Africaine

Selon Oxfam International...l’industrie pharmaceutique empêche des millions de personnes pauvres d’avoir accès aux médicaments, mettant ainsi en péril son propre devenir...Sanofi-Aventis proposait son médicament ...Plavix à un prix 60 fois supérieur à ...[la] version générique indienne du médicament...Pfizer a ainsi intenté un procès au gouvernement des Philippines pour l’usage de clauses de sauvegarde invoquant la santé publique à l’égard du médicament Norvasc...

🚫Read the full post here

Article
1 November 2007

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Author: Oxfam

Access to medicines is fundamental for people to achieve their right to health. While governments have the primary responsibility for ensuring access to health care...the role of the pharmaceutical industry in providing a vital element – medicines – carries its own responsibilities...Current industry approaches do not address the problem sufficiently. Major shortcomings include: a failure to implement systematic and transparent tiered-pricing mechanisms for medicines of therapeutic value to poor people...lack of research and development (R&D) to address the dearth of dedicated products for diseases that predominantly affect poor people...persistent inflexibility on intellectual property protection...too heavy a focus on donations...[refers to Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth]

Read the full post here